Quality meltdown still affects J&J financials, though Q3 sales are up

Johnson & Johnson ($JNJ) reports today in third-quarter financials that U.S. sales of OTC medicines were "significantly impacted" by the shutdown of McNeil's Consumer Healthcare manufacturing plant in Fort Washington, PA, the main player in its many Tylenol recalls over the last two years. In addition, ongoing remediation work lowered production volumes. Nonetheless, overall sales were up nearly 7% over last year's Q3. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.